Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield? Platform, in Patients with Solid Tumors

Published: 2025-06-02 10:20:41 ET IBRX

Published on 06/02/2025 at 10:20

ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield? platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy.